vs
Side-by-side financial comparison of Evolus, Inc. (EOLS) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Evolus, Inc. is the larger business by last-quarter revenue ($73.1M vs $70.6M, roughly 1.0× Viridian Therapeutics, Inc.\DE). Evolus, Inc. runs the higher net margin — -14.6% vs -49.0%, a 34.4% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 6.7%).
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing non-surgical cosmetic treatment solutions. Its flagship product is a prescription neuromodulator designed to reduce moderate to severe glabellar frown lines, serving licensed aesthetic healthcare providers and consumers across North America, Europe, and key Asia-Pacific regional markets.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
EOLS vs VRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.1M | $70.6M |
| Net Profit | $-10.7M | $-34.6M |
| Gross Margin | 66.9% | — |
| Operating Margin | 23.8% | -56.7% |
| Net Margin | -14.6% | -49.0% |
| Revenue YoY | 6.7% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-0.16 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $73.1M | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $69.0M | $70.6M | ||
| Q2 25 | $69.4M | — | ||
| Q1 25 | $68.5M | — | ||
| Q4 24 | $78.9M | — | ||
| Q3 24 | $61.1M | — | ||
| Q2 24 | $66.9M | — |
| Q1 26 | $-10.7M | — | ||
| Q4 25 | $130.0K | — | ||
| Q3 25 | $-15.7M | $-34.6M | ||
| Q2 25 | $-17.1M | — | ||
| Q1 25 | $-18.9M | — | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-19.2M | — | ||
| Q2 24 | $-11.3M | — |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 65.7% | — | ||
| Q3 25 | 66.5% | — | ||
| Q2 25 | 65.3% | — | ||
| Q1 25 | 68.1% | — | ||
| Q4 24 | 66.7% | — | ||
| Q3 24 | 68.9% | — | ||
| Q2 24 | 70.3% | — |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | -16.7% | -56.7% | ||
| Q2 25 | -14.7% | — | ||
| Q1 25 | -22.1% | — | ||
| Q4 24 | -2.9% | — | ||
| Q3 24 | -25.3% | — | ||
| Q2 24 | -11.5% | — |
| Q1 26 | -14.6% | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | -22.8% | -49.0% | ||
| Q2 25 | -24.7% | — | ||
| Q1 25 | -27.6% | — | ||
| Q4 24 | -8.6% | — | ||
| Q3 24 | -31.4% | — | ||
| Q2 24 | -17.0% | — |
| Q1 26 | $-0.16 | — | ||
| Q4 25 | $0.01 | — | ||
| Q3 25 | $-0.24 | — | ||
| Q2 25 | $-0.27 | — | ||
| Q1 25 | $-0.30 | — | ||
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $-0.18 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.8M | $490.9M |
| Total DebtLower is stronger | $156.4M | — |
| Stockholders' EquityBook value | — | $503.0M |
| Total Assets | $220.6M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $49.8M | — | ||
| Q4 25 | $53.8M | — | ||
| Q3 25 | $43.5M | $490.9M | ||
| Q2 25 | $61.7M | — | ||
| Q1 25 | $67.9M | — | ||
| Q4 24 | $87.0M | — | ||
| Q3 24 | $85.0M | — | ||
| Q2 24 | $93.7M | — |
| Q1 26 | $156.4M | — | ||
| Q4 25 | $146.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $121.8M | — | ||
| Q4 24 | $121.5M | — | ||
| Q3 24 | $121.2M | — | ||
| Q2 24 | $120.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-23.1M | — | ||
| Q3 25 | $-28.8M | $503.0M | ||
| Q2 25 | $-18.7M | — | ||
| Q1 25 | $-6.6M | — | ||
| Q4 24 | $5.5M | — | ||
| Q3 24 | $5.9M | — | ||
| Q2 24 | $19.3M | — |
| Q1 26 | $220.6M | — | ||
| Q4 25 | $225.9M | — | ||
| Q3 25 | $219.0M | $577.1M | ||
| Q2 25 | $228.8M | — | ||
| Q1 25 | $213.4M | — | ||
| Q4 24 | $232.6M | — | ||
| Q3 24 | $229.6M | — | ||
| Q2 24 | $233.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 22.00× | — | ||
| Q3 24 | 20.58× | — | ||
| Q2 24 | 6.26× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $12.8M | — | ||
| Q3 25 | $-14.7M | $-84.6M | ||
| Q2 25 | $-24.8M | — | ||
| Q1 25 | $-15.6M | — | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $-5.7M | — | ||
| Q2 24 | $-6.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | $11.3M | — | ||
| Q3 25 | $-15.6M | $-84.7M | ||
| Q2 25 | $-25.5M | — | ||
| Q1 25 | $-16.0M | — | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $-6.0M | — | ||
| Q2 24 | $-6.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | — | ||
| Q3 25 | -22.7% | -120.1% | ||
| Q2 25 | -36.7% | — | ||
| Q1 25 | -23.3% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | -9.9% | — | ||
| Q2 24 | -10.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.4% | 0.2% | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 98.67× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EOLS
| Product revenue, net | $72.7M | 99% |
| Service revenue | $390.0K | 1% |
VRDN
Segment breakdown not available.
